Trial reportPloS one2010
Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.
Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00118677 (Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO
Who cites it
29 citing papers in PubMed.
- The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation.PLoS pathogens · 2013Trial
- Trial
- Immunosenescence and immune dysfunction in treated and untreated HIV-infected individuals.The Indian journal of medical research · 2026Article
- Myeloid-derived suppressor cells and the pathogenesis of human immunodeficiency virus infection.Open biology · 2021Review
- High-frequency and activation of CD4Veterinary research · 2021Article
- The role of CD38 in HIV infection.AIDS research and therapy · 2021Review
- Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders.Molecular neurodegeneration · 2020Review
- Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV.Journal of immunology research · 2020Review
- Delineation of Homeostatic Immune Signatures Defining Viremic Non-progression in HIV-1 Infection.Frontiers in immunology · 2020Article
- Foxp3BMC immunology · 2019Article
- Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.Frontiers in immunology · 2018Article
- Regulatory T Cell Effect on CD8AIDS research and human retroviruses · 2017Article
- Potential Role of Vδ2Frontiers in immunology · 2017Article
- Article
- T-Cell Activation Independently Associates With Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment.The Journal of infectious diseases · 2016Article
- Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression.Frontiers in immunology · 2016Review
- Epigenetic modification of FOXP3 in patients with chronic HIV infection.Journal of acquired immune deficiency syndromes (1999) · 2014Article
- Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals.AIDS research and human retroviruses · 2013Article
- HIV-associated chronic immune activation.Immunological reviews · 2013Review
- Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach.AIDS (London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledPersistent immune activation plays a central role in driving Human Immunodeficiency Virus (HIV) disease progression. Whether CD4+CD25+ regulatory T cells (Tregs) are harmful by suppressing HIV-specific immune responses and/or beneficial through a decrease in immune activation remains debatable. We analysed the relationship between proportion and number of regulatory T cells (Tregs) and immune activation in HIV-infected patients interrupting an effective antiretroviral therapy (ART). Twenty-five patients were included in a substudy of a prospective multicenter trial of treatment interruption (TI) (ANRS 116). Proportions and numbers of Tregs and the proportion of activated CD4 and CD8 T cells were assessed at baseline and month 12 (M12) of TI. Specific anti-HIV CD4 and CD8 responses were investigated at baseline and M12. Non parametric univariate analyses and multivariate linear regression models were conducted. At baseline, the proportion of Tregs negatively correlated with the proportion of HLA-DR+CD8+T cells (r=-0.519). Following TI, the proportion of Tregs increased from 6.3% to 7.2% (p=0.029); absolute numbers of Tregs decreased. The increase in the proportion of HLA-DR+CD38+CD8+T cells was significantly related to the increase in proportion of Tregs (p=0.031). At M12, the proportion of Tregs did not negatively correlate with CD8 T-cell activation. Nevertheless, Tregs retain a suppressive function since depletion of Treg-containing CD4+CD25+ cells led to an increase in lymphoproliferative responses in most patients studied. Our data suggest that Tregs are efficient in controlling residual immune activation in patients with ART-mediated viral suppression. However, the insufficient increase in the proportion and/or the decrease in the absolute number of Tregs result in a failure to control immune activation following TI.
trial registrationClinicalTrials.gov NCT00118677.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.